95-95-95 targets — LLMpedia

95-95-95 targets
Name	95-95-95 targets
Type	Public health initiative
Established	2014
Aim	Diagnosis, treatment, viral suppression targets for HIV/AIDS
Related	Joint United Nations Programme on HIV/AIDS, World Health Organization, Global Fund

Contents

95-95-95 targets The 95-95-95 targets are global HIV/AIDS benchmarks established to accelerate epidemic control by defining diagnostic, therapeutic, and virologic goals. Endorsed by Joint United Nations Programme on HIV/AIDS and promoted alongside World Health Organization, Global Fund to Fight AIDS, Tuberculosis and Malaria, and national health agencies, the targets build on earlier initiatives like Millennium Development Goals and Sustainable Development Goals. They inform policy debates involving actors such as UNAIDS program offices, Centers for Disease Control and Prevention technical partners, and civil society networks exemplified by Médecins Sans Frontières.

Background and Rationale

The framework emerged from modelling work by UNAIDS and advisory input from World Health Organization experts, drawing on evidence from trials supported by National Institutes of Health, Bill & Melinda Gates Foundation, and operational research in settings like South Africa, Kenya, and Uganda. Policymakers compared the approach with precedents including PEPFAR, Global Fund to Fight AIDS, Tuberculosis and Malaria, and targets under Sustainable Development Goals to justify ambitious thresholds. Advocates from AmfAR, International AIDS Society, and community groups emphasized lessons from President's Emergency Plan for AIDS Relief rollout and outcomes reported in cohorts linked to University of Cape Town and Johns Hopkins University research units.

The targets specify that by a target year 95% of all people living with HIV should know their status, 95% of diagnosed individuals should receive sustained antiretroviral therapy, and 95% of those on therapy should achieve virologic suppression—metrics tracked by agencies such as UNAIDS, WHO, PEPFAR, and national programs modeled after surveillance systems at European Centre for Disease Prevention and Control and Centers for Disease Control and Prevention. Implementation relies on laboratory networks akin to those coordinated by Association of Public Health Laboratories and monitoring frameworks comparable to indicators used by Global Fund to Fight AIDS, Tuberculosis and Malaria grants. Epidemiological modelling from institutions like Imperial College London, Harvard University, and London School of Hygiene & Tropical Medicine informs assumptions about cascade losses and transmission dynamics.

Countries operationalize the targets through strategies pioneered in programs supported by PEPFAR, Global Fund to Fight AIDS, Tuberculosis and Malaria, Clinton Health Access Initiative, and partnerships with private-sector actors like Gilead Sciences and ViiV Healthcare. Key tactics include community-based testing initiatives inspired by campaigns in Botswana, differentiated service delivery models trialed in Zambia, and treatment-as-prevention protocols evaluated in studies linked to University of Oxford and McGill University. Integration with maternal-child health platforms used in Rwanda and harm-reduction services modeled after projects in Portugal and Netherlands enhances reach, while supply-chain reforms draw on logistics systems developed by United Nations Children's Fund and procurement models from World Bank programs.

Progress reports by UNAIDS and WHO show heterogeneous performance: regions such as Western Europe and North America and parts of East Asia report higher coverage, while regions including Sub-Saharan Africa, Eastern Europe and Central Asia, and some areas of Latin America and the Caribbean face gaps. National case studies from Botswana, Thailand, and Eswatini illustrate near-target achievement attributed to domestic financing, whereas countries like Russia and Ukraine face barriers linked to policy and service access. Multilateral financers such as Global Fund to Fight AIDS, Tuberculosis and Malaria and bilateral partners like United States Agency for International Development publish disaggregated data used by researchers at Columbia University and University of Washington to evaluate trends.

Barriers include stigma and discrimination documented in studies by Human Rights Watch and Amnesty International, legal impediments highlighted in reports on criminalization of key populations by International Commission of Jurists, and supply limitations noted by World Health Organization and procurement analyses from UNICEF. Additional challenges stem from coinfections like Mycobacterium tuberculosis and structural determinants examined by scholars at London School of Hygiene & Tropical Medicine and Harvard T.H. Chan School of Public Health, as well as funding volatility tracked by Global Fund to Fight AIDS, Tuberculosis and Malaria and policy shifts influenced by actors such as United States Congress and European Commission.

Where implemented effectively, the cascade targets contributed to declines in HIV incidence and AIDS-related mortality reported by UNAIDS, with modeled impacts corroborated by analyses from Imperial College London, University of California, San Francisco, and Karolinska Institutet. Health systems strengthening from target-driven investments echoes reforms supported by World Bank and Asian Development Bank, and community-led service models promoted by Frontline AIDS and International Treatment Preparedness Coalition improved retention and viral suppression. Persistent inequities underscore ongoing work by global actors including UNAIDS, WHO, Global Fund to Fight AIDS, Tuberculosis and Malaria, and civil society to translate targets into universal access.